arrow
M

Marc S. Sabatine

Harvard Medical School
H指数:143
被引数:12.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics

HPS-4/TIMI 65/ORION-4:一项双盲、随机、安慰剂对照试验,评估依洛尤单抗对动脉粥样硬化性心血管疾病患者临床结局的影响:试验设计、招募和基线特征

2026-09-010
PRE
2026-08-300
OAAI
Evolocumab and risk of first myocardial infarction: the VESALIUS-CV trial

依洛尤单抗与首次心肌梗死风险:VESALIUS-CV试验

2026-08-280
OAAI
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study

AZALEA-TIMI 71研究中因子XI抑制剂abellacimab的既往抗凝治疗经验与出血风险

Blood
IF23.1
2026-08-011
PRE
Use of a polygenic risk score to enhance early detection of coronary atherosclerosis

使用多基因风险评分以增强冠状动脉粥样硬化的早期检测

2026-03-230
OAAI
A polygenic risk score for peripheral artery disease and major adverse limb events

外周动脉疾病及主要肢体不良事件的polygenic risk score

2025-11-010
PRE
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk

奥利泽森(Olezarsen)用于管理严重高甘油三酯血症及胰腺炎风险

2025-11-015
PRE
Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trials

个体参与者数据meta分析中系统缺失协变量的统计方法:基于5项大型心血管试验的见解与应用

2025-11-010
OA
Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease

动脉粥样硬化疾病谱中冠状动脉疾病的多基因风险评分

2025-11-010
PRE
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial

抗体介导的LOX-1抑制在心肌梗死后残留炎症患者中的疗效:一项随机第2期临床试验

2025-09-250
PRE
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation

致病性心肌病相关基因变异与心房颤动的预后

JACC
IF0
2025-09-010
PRE
Multicenter Prospective Assessment of Coronary Microvascular Dysfunction Primary Results of the FlowLab Study

多中心前瞻性评估冠状动脉微血管功能障碍——FlowLab研究的初步结果

2025-09-011
OAAI
Dapagliflozin, Heart Failure, and Duration of Diabetes

达格列净、心力衰竭和糖尿病持续时间

2025-08-290
OAAI
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

2025年《2019 ESC/EAS血脂异常管理指南》聚焦更新版

2025-08-290
PRE
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk

一种用于预测全谱心血管风险范围内新发心力衰竭的多基因风险评分

JACC
IF0
2025-08-270
PRE
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trial

生长分化因子-15及达格列净在心力衰竭中的效果:DAPA-HF试验的启示

2025-08-150
OAAI